Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
PARIS, France, May 8, 2024, 8:30 a.m. CEST – Abivax SA (Abivax or the Company), a clinical-stage biotechnology company, unveils the upcoming presentation of four scientific abstracts on its lead drug candidate, obefazimod, at Digestive Disease Week (DDW) 2024 in Washington D.C. The abstracts focus on obefazimod’s potential in treating ulcerative colitis and its impact in a preclinical colon cancer model.
Presenting the latest findings on obefazimod, Sheldon Sloan, M.D., Chief Medical Officer of Abivax, expresses anticipation for engaging with the IBD community on the drug’s emerging clinical profile and novel mechanisms of action. The Company is set to share new preclinical data highlighting obefazimod’s ability to reduce tumor numbers in a colon cancer model.
To gain more insights into obefazimod’s potential, attendees are encouraged to visit Abivax’s exhibition booth (#529) at DDW or attend the Product Theater presentation led by Prof. Parambir S. Dulai, M.D., on May 20, 2024. The investigative new MOA that stabilizes the inflammatory response in Ulcerative Colitis will be a focal point of discussion.
Abivax’s lead candidate, obefazimod, has shown promise in Phase 2 clinical trials for UC, leading to the initiation of a pivotal Phase 3 clinical trial program (ABTECT Program). Further clinical trials in Crohn’s disease are on the horizon, along with exploring combination therapy opportunities for UC.
Abivax’s dedication to developing therapeutic solutions for chronic inflammatory diseases is underscored by its commitment to presenting cutting-edge research at DDW 2024. Industry professionals and stakeholders alike eagerly anticipate the valuable insights that Abivax will bring to the table during this prestigious event.
